Launch event – 25 May 2024 at Living Tomorrow
Novartis organized an event in May 2024 to launch the reimbursement of our latest treatment for Metastatic castration-resistant Prostate Cancer (mCRPC) for health care professionals involved in the treatment of these patients. This event had a mixed of international and national experts discussing the latest development in precision medicine as well as challenging patient cases.
BE2404104679
